Objective: Evaluation of Aidi injection combined with GP program from the perspective of evidence-based medical system for treatment of non-small cell lung cancer(NSCLS) clinical efficacy and safety. Method: CBM

CNKI

VIP

Wanfang Data and PubMed were searched for the clinical randomized controlled trials on Aidi injection auxiliary GP regimen for NSCLC.The studies were screened according to inclusion and exclusion criteria;the trials were evaluated in accordance with the quality evaluation standard in Cochrane 5.1.0 Manual

and Meta-analysis was conducted by using Revman 5.3 software. Result: A total of 15 clinical randomized controlled trials were included in the systematic review

and the analysis results showed that:Aidi injection auxiliary GP regimen could significantly increase the effective rate [OR=1.57

95%CI (1.23

2.01)

P=0.000 3] and quality of life [OR=3.20

95%CI (2.41

4.25)

P < 0.000 01]

reduce leukocytes [OR=0.52

95%CI (0.35

0.77)

P=0.001] and thrombocytopenia [OR=0.43

95%CI (0.29

0.63)

P < 0.000 1]

and reduce gastrointestinal side effects [OR=0.53

95%CI (0.40

0.69)

P < 0.000 01]

with statistically significant difference;but there was no significant difference with GP regimen alone in decreased hemoglobin [OR=0.82

95%CI (0.41

1.64)

P=0.57]

liver dysfunction [OR=0.74

95%CI (0.47

1.15)

P=0.18] and renal impairment [OR=0.70

95%CI (0.40

1.23)

P=0.21]. Conclusion: Aidi injection combined with GP treatment of NSCLC for better clinical effect than a simple GP chemotherapy

reduce side effects caused by chemotherapy section. But the included studies of low methodological quality

but also high-quality clinical studies further confirmed.